Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 10/2012

01.10.2012 | Therapy In Practice

Acute Treatment of Migraines

verfasst von: Dr Arnaldo N. Da Silva, Dr Stewart J. Tepper

Erschienen in: CNS Drugs | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

Migraine is a prevalent and disabling brain disorder that costs billions of dollars annually in direct healthcare costs, and school and work absenteeism and presenteeism. The objective of acute treatment is a cost-effective, rapid restoration of functional ability, with minimal recurrence and adverse effects.
The acute treatment of migraine includes specific drugs, which currently all have vasoconstrictive effects (dihydroergotamine and triptans), and nonspecific drugs that include paracetamol (acetaminophen), combination analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), dopamine antagonists, narcotics and corticosteroids.
NSAIDs have both peripheral and central effects on reversing migraine, and so may represent the best alternative for patients who cannot use triptans and ergots due to vascular contraindications. Narcotics and habituating medications should be avoided in the acute treatment of migraine, as the risk for transformation to chronic daily headache is excessively high at a relatively infrequent rate of exposure.
Literatur
1.
Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO’ Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005 Dec; 6(6): 429–40PubMedCrossRef
2.
Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 Jul–Aug; 41(7): 646–57PubMedCrossRef
3.
Stewart WF, Ricci JA, Chee E, et al. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med 2003 Dec; 45(12): 1234–46PubMedCrossRef
4.
Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005 Jun; 12 Suppl. 1: 1–27PubMedCrossRef
5.
Tepper SJ, Dahlof CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004 Oct; 44(9): 856–64PubMedCrossRef
6.
Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011 Sep 20; 12(10): 570–84PubMedCrossRef
7.
Charles A. Advances in the basic and clinical science of migraine. Ann Neurol 2009 May; 65(5): 491–8PubMedCrossRef
8.
Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003 May; 4(5): 386–98PubMedCrossRef
9.
Lambert GA, Truong L, Zagami AS. Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system. Cephalalgia 2011 Oct; 31(14): 1439–51PubMedCrossRef
10.
Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 Sep 26; 55(6): 754–62PubMedCrossRef
11.
12.
Lipton RB, Stewart WF, Stone AM, et al., Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000 Nov 22–29; 284(20): 2599–605PubMedCrossRef
13.
Tepper SJ. Acute treatment of migraine. Continuum 2006; 12(6): 87–105
14.
Edmeads J, Lainez JM, Brandes JL, et al. Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice. Neurology 2001; 56 (6 Suppl. 1): S29–34PubMedCrossRef
15.
Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001; 56 (6 Suppl. 1): S20–8PubMedCrossRef
16.
Stewart WF, Lipton RB, Kolodner KB, et al. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000 Oct; 88(1): 41–52PubMedCrossRef
17.
Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999 Sep 22; 53(5): 988–94PubMedCrossRef
18.
Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 2003 Dec; 12(8): 963–74PubMedCrossRef
19.
Sculpher M, Millson D, Meddis D, et al. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: the Disability in Strategies for Care (DISC) Study. Pharmacoeconomics 2002; 20(2): 91–100PubMedCrossRef
20.
Berde B, Sturmer E. Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In: Berde B, Shild HO, editors. Ergot alkaloids and related compounds. New York (NY): Springer-Verlag, 1978CrossRef
21.
Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006 Nov; 46 Suppl. 4: S171–81PubMedCrossRef
22.
Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993 Jan; 33(1): 48–56PubMedCrossRef
23.
Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988 Jun; 8(2): 83–91PubMedCrossRef
24.
Muller-Schweinitzer E. Venoconstrictor responses to dihydroergocristine and dihydroergotamine: evidence for the involvement of 5-HT1 like receptors. Cardiovasc Drugs Ther 1990 Dec; 4(6): 1455–60PubMedCrossRef
25.
Muller-Schweinitzer E, Rosenthaler J. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs. J Cardiovasc Pharmacol 1987 Jun; 9(6): 686–93PubMedCrossRef
26.
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium. Headache 2012 Jan; 52(1): 114–28PubMedCrossRef
27.
Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin 1990 Nov; 8(4): 801–15PubMed
28.
Masterson CG, Durham PL. DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons. Headache 2010 Oct; 50(9): 1424–39PubMedCrossRef
29.
Nagy AJ, Gandhi S, Bhola R, et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology 2011 Nov 15; 77(20): 1827–32PubMedCrossRef
30.
Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Mayo Clin Proc 1945; 20: 241–8
31.
Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986 Apr; 26(4): 168–71PubMedCrossRef
32.
Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986 Jul; 36(7): 995–7PubMedCrossRef
33.
Belgrade MJ, Ling LJ, Schleevogt MB, et al. Comparison of single-dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache. Neurology 1989 Apr; 39(4): 590–2PubMedCrossRef
34.
Bell R, Montoya D, Shuaib A, et al. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med 1990 Oct; 19(10): 1079–82PubMedCrossRef
35.
Klapper JA, Stanton JS. Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Headache 1991 Sep; 31(8): 523–4PubMedCrossRef
36.
Klapper JA, Stanton JS. The emergency treatment of acute migraine headache; a comparison of intravenous dihydroergotamine, dexamethasone, and placebo. Cephalalgia 1991; 11 Suppl. 11: 159–60
37.
Haugh MJ, Lavender L, Jensen A, et al. An office-based double-blind comparison of dihydroergotamine vs dihydroergotamine/metoclopramide in the treatment of acute migraine [abstract]. Headache 1992; 32: 251CrossRef
38.
Saadah HA. Abortive headache therapy in the office with intravenous dihydroergotamine plus prochlorperazine. Headache 1992 Mar; 32(3): 143–6PubMedCrossRef
39.
Klapper JA, Stanton J. Current emergency treatment of severe migraine headaches. Headache 1993 Nov–Dec; 33(10): 560–2PubMedCrossRef
40.
Scherl ER, Wilson JF. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache 1995 May; 35(5): 256–9PubMedCrossRef
41.
Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996 Feb; 53(2): 180–4PubMedCrossRef
42.
Carleton SC, Shesser RF, Pietrzak MP, et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med 1998 Aug; 32(2): 129–38PubMedCrossRef
43.
Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001 Nov–Dec; 41(10): 976–80PubMedCrossRef
44.
Swidan SZ, Lake AE, Saper JR. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache. Curr Pain Headache Rep 2005 Feb; 9(1): 65–70PubMedCrossRef
45.
Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus: Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology 1995 Mar; 45(3 Pt 1): 577–84PubMedCrossRef
46.
Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. Headache 2008 Mar; 48(3): 355–67PubMedCrossRef
47.
Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 2011 Apr; 51(4): 507–17PubMedCrossRef
48.
Tepper SJ, Kori SH, Goadsby PJ, et al. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc 2011 Oct; 86(10): 948–55PubMedCrossRef
49.
Saxena PR, Ferrari MD. 5-HT(1)-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989 May; 10(5): 200–4PubMedCrossRef
50.
Hargreaves RJ, Shepheard SL. Pathophysiology of migraine: new insights. Can J Neurol Sci 1999 Nov; 26 Suppl. 3: S12–9PubMed
51.
Humphrey PP, Apperly E, Feniuk W, et al. A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena PR, Wallis DI, Wouters W, et al., editors. Cardiovascular pharmacology of 5-hydroxytryptamine. Dordrecht: Kluwer Academic Publishers, 1990:417–31
52.
Humphrey PP, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 1989; 9 Suppl. 9: 23–33PubMed
53.
Humphrey PP, Feniuk W, Perren MJ, et al. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 1988 Aug; 94(4): 1123–32PubMedCrossRef
54.
Rapoport AM, Tepper SJ, Bigal ME, et al. The triptan formulations: how to match patients and products. CNS Drugs 2003; 17(6): 431–47PubMedCrossRef
55.
Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache 2010 Feb; 50(2): 264–72PubMedCrossRef
56.
McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database Syst Rev 2003; 3(3): CD002915PubMed
57.
Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache 2009 Jul; 49(7): 971–82PubMedCrossRef
58.
Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005 Sep; 45(8): 983–91PubMedCrossRef
59.
Akpunonu BE, Mutgi AB, Federman DJ, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med 1995 Apr; 25(4): 464–9PubMedCrossRef
60.
Kelly AM, Ardagh M, Curry C, et al. Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine. J Accid Emerg Med 1997 Jul; 14(4): 209–11PubMedCrossRef
61.
Hay E, Rodrig J, Hussain A, et al. Rizatriptan RPD for severe migraine in the emergency department: a multicenter study. J Emerg Med 2003 Oct; 25(3): 245–9PubMedCrossRef
62.
Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med 2003 May; 21(3): 173–5PubMedCrossRef
63.
Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005 Feb 8; 64(3): 463–8PubMedCrossRef
64.
Friedman BW, Hochberg M, Esses D, et al. A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. Headache 2006 Jun; 46(6): 934–41PubMedCrossRef
65.
Miner JR, Smith SW, Moore J, et al. Sumatriptan for the treatment of undifferentiated primary headaches in the ED. Am J Emerg Med 2007 Jan; 25(1): 60–4PubMedCrossRef
66.
Kostic MA, Gutierrez FJ, Rieg TS, et al. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med 2010 Jul; 56(1): 1–6PubMedCrossRef
67.
Suthisisang CC, Poolsup N, Suksomboon N, et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 2010 May; 50(5): 808–18PubMedCrossRef
68.
Suthisisang C, Poolsup N, Kittikulsuth W, et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 2007 Nov; 41(11): 1782–91PubMedCrossRef
69.
Jakubowski M, Levy D, Goor-Aryeh I, et al. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005 Jul–Aug; 45(7): 850–61PubMedCrossRef
70.
Diener HC, Montagna P, Gacs G, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia 2006 May; 26(5): 537–47PubMedCrossRef
71.
Lipton RB, Grosberg B, Singer RP, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia 2010 Nov; 30(11): 1336–45PubMedCrossRef
72.
Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 2012 Feb; 14(1): 27–35PubMedCrossRef
73.
Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology 1997 Jul; 49(1): 201–6PubMedCrossRef
74.
Fernandez F, Lea RA, Colson NJ, et al. Association between a 19 bp deletion polymorphism at the dopamine beta-hydroxylase (DBH) locus and migraine with aura. J Neurol Sci 2006 Dec 21; 251(1–2): 118–23PubMedCrossRef
75.
76.
Colman I, Brown MD, Innes GD, et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ 2004 Dec 11; 329(7479): 1369–73PubMedCrossRef
77.
Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med 2002 Aug; 23(2): 141–8PubMedCrossRef
78.
Shrestha M, Singh R, Moreden J, et al. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura: a prospective, randomized, double-blind trial. Arch Intern Med 1996 Aug 12–26; 156(15): 1725–8PubMedCrossRef
79.
Jones J, Sklar D, Dougherty J, et al. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA 1989 Feb 24; 261(8): 1174–6PubMedCrossRef
80.
Seim MB, March JA, Dunn KA. Intravenous ketorolac vs intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med 1998 Jun; 5(6): 573–6PubMedCrossRef
81.
Ginder S, Oatman B, Pollack M. A prospective study of i.v. magnesium and i.v. prochlorperazine in the treatment of headaches. J Emerg Med 2000 Apr; 18(3): 311–5PubMedCrossRef
82.
Derry S, Moore RA, McQuay HJ. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2010 Nov 10; 11(11): CD008040PubMed
83.
Tfelt-Hansen P, Olesen J. Paracetamol (acetaminophen) versus acetylsalicylic acid in migraine. Eur Neurol 1980; 19(3): 163–5PubMedCrossRef
84.
Lipton RB, Stewart WF, Ryan Jr RE, et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998 Feb; 55(2): 210–7PubMedCrossRef
85.
Goldstein J, Hoffman HD, Armellino JJ, et al. Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers: results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin, and caffeine. Cephalalgia 1999 Sep; 19(7): 684–91PubMedCrossRef
86.
Diener HC, Pfaffenrath V, Pageler L, et al. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005 Oct; 25(10): 776–87PubMedCrossRef
87.
Freitag FG, Cady R, DiSerio F, et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache 2001 Apr; 41(4): 391–8PubMedCrossRef
88.
Moskowitz MA, Cutrer FM. Sumatriptan: a receptortargeted treatment for migraine. Annu Rev Med 1993; 44: 145–54PubMedCrossRef
89.
May A, Shepheard SL, Knorr M, et al. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain 1998 Jul; 121(Pt 7): 1231–7PubMedCrossRef
90.
Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology 2007 Nov 27; 69(22): 2038–44PubMedCrossRef
91.
Donaldson D, Sundermann R, Jackson R, et al. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial. Am J Emerg Med 2008 Feb; 26(2): 124–30PubMedCrossRef
92.
Rowe BH, Colman I, Edmonds ML, et al. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache. Headache 2008 Mar; 48(3): 333–40PubMedCrossRef
93.
Fiesseler FW, Shih R, Szucs P, et al. Steroids for migraine headaches: a randomized double-blind, two-armed, placebo-controlled trial. J Emerg Med 2011 Apr; 40(4): 463–8PubMedCrossRef
94.
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache 2012 Mar; 52(3): 467–82PubMedCrossRef
95.
Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008 Nov 25; 71(22): 1821–8PubMedCrossRef
96.
Members of the task force:, Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur J Neurol 2006 Jun; 13(6): 560–72PubMedCrossRef
Metadaten
Titel
Acute Treatment of Migraines
verfasst von
Dr Arnaldo N. Da Silva
Dr Stewart J. Tepper
Publikationsdatum
01.10.2012
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 10/2012
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11635440-000000000-00000

Weitere Artikel der Ausgabe 10/2012

CNS Drugs 10/2012 Zur Ausgabe

Original Research Article

Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder

Review Article

Frontotemporal Lobar Degeneration

Adis Drug Clinical Q&A

Oromucosal Midazolam: A Guide to Its Use in Paediatric Patients with Prolonged Acute Convulsive Seizures

Review Article

Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection

Adis Drug Evaluation

Alteplase

Current Opinion

Further Findings Linking SSRIs During Pregnancy and Persistent Pulmonary Hypertension of the Newborn

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise